Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • pmiguel
    Senior Member
    • Aug 2008
    • 2328

    #1

    Goofy profit reporting in GenomeWeb

    I've seen a couple of these recently here and here.

    The articles begin by trumpeting increases in revenue:

    Affymetrix reported after the close of the market Thursday that its first quarter revenues increased around 7 percent year over year and beat the consensus Wall Street estimate.
    Pacific Biosciences reported after the close of the market Wednesday that its first quarter 2014 revenues more than doubled year over year and grew 27 percent sequentially.
    But if you look lower, a lot lower, in the text you find:

    Affy posted a net loss of $10.5 million, or $.14 per share, for the quarter, compared to a loss of $15.4 million, or $.22 per share, for Q1 2013.
    and

    The company posted a net loss for the quarter of $18.9 million, or $.28 per share, down from its net loss of $21.1 million
    --
    Phillip
  • Richard Finney
    Senior Member
    • Feb 2009
    • 701

    #2
    Welcome to Silicon Valley. The game is musical chairs.
    Knowing when the Sand Hill insiders are going to stop the music is part of this game.

    Comment

    • MrGuy
      Member
      • Mar 2009
      • 68

      #3
      You are mixing up Revenues with Earnings. They aren't the same thing. Revenue is the amount of money the company brought in. Earnings is the expenses (overhead, operations, R&D, etc) that are subtracted from the revenues providing you with Gross Earnings. Net earnings is after taxes and similar.

      Thus, a company can spend more money than it makes and tout their great increases in revenues.

      Comment

      • pmiguel
        Senior Member
        • Aug 2008
        • 2328

        #4
        Originally posted by MrGuy View Post
        You are mixing up Revenues with Earnings. They aren't the same thing. Revenue is the amount of money the company brought in. Earnings is the expenses (overhead, operations, R&D, etc) that are subtracted from the revenues providing you with Gross Earnings. Net earnings is after taxes and similar.

        Thus, a company can spend more money than it makes and tout their great increases in revenues.
        So, out of curiosity, if you see a company that reports increased revenues quarter to quarter are you thinking: "I should buy some of that stock"? That is what I really mean to ask. Is there some intrinsic value in the stock of a company that is showing increased revenues, but negative earnings?

        Seems like a company that is losing money should be a bad investment. If that is the case, then it does not seem to me that a news source should be trumpeting increases in revenue in the first paragraph and holding off until the later in the story to mention negative earnings.

        However, I have little knowledge in this area.

        --
        Phillip

        Comment

        • Brian Bushnell
          Super Moderator
          • Jan 2014
          • 2709

          #5
          New companies typically have revenue before profits. If revenue is growing fast, and losses are decreasing, that's good; the assumption is that with enough revenue, the company will be profitable. If revenue is flat and the company is losing money, that's bad. If revenue and losses are both increasing at the same rate, that indicates there's something fundamentally wrong with the company's business model.

          Investing in companies that have never shown a profit is inherently risky because they may never become profitable, but that does not mean they are a bad investment, just a risky one.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            Yesterday, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Yesterday, 05:39 AM
          0 responses
          12 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-13-2026, 09:56 AM
          0 responses
          14 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-09-2026, 11:14 AM
          0 responses
          27 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 09-29-2026, 09:51 AM
          0 responses
          78 views
          0 reactions
          Last Post SEQadmin2  
          Working...